Ureteral stenting in patients with bladder cancer may become necessary in order to protect the ureteral orifice during transurethral resection of the tumor or for relief of upper urinary tract (UUT) obstruction.
Calls on Congress, the Administration, and the health care community to eliminate disparities San Francisco, CA (UroToday.com) — The American Society of Clinical Oncology (ASCO) issued comprehensive recommendations to guide the cancer community’s eventual recovery from the COVID-19 pandemic. By applying lessons learned during the pandemic, ASCO’s Road to Recovery Report: Learning from the COVID-19 Experience […]
(UroToday.com) Inguinal lymph node dissection is a core component in the management of penile squamous cell carcinoma with involvement, or a high risk of involvement, of the inguinal lymph nodes. Available information is lacking regarding the exact incidence, site, and timing of recurrence after inguinal lymph node dissection. Such knowledge would be critically useful to inform […]
We sought to examine the effect of tumor location on the prognosis of patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy (RNU). This retrospective study came from the Taiwan UTUC Collaboration Group, which consisted of 2658 patients at 15 institutions in Taiwan from 1988 to 2019.
Based on the eighth TNM staging system, T3a renal cell carcinoma (RCC) is identified as an anatomical extrarenal invasion and does not consider the size of the tumor; however, it may not fully predict the prognosis of the patient.
The modified Glasgow prognostic score (mGPS), which incorporates serum albumin and C-reactive protein levels, reflects systemic inflammation and nutritional status. In this study, we evaluate the role of mGPS as a predictor of prognosis in metastatic renal cell carcinoma treated with nivolumab.
The Canadian Kidney Cancer information system (CKCis) has prospectively collected data on patients with renal tumors since January 1, 2011 from 16 sites within 14 academic centers in six provinces. Canadian kidney cancer experts have used CKCis data to address several research questions.
Selective ERα modulator, tamoxifen, is well tolerated in a heavily pretreated castration-resistant prostate cancer (PCa) patient cohort. However, its targeted gene network and whether expression of intratumor ERα due to androgen-deprivation therapy (ADT) may play a role in PCa progression is unknown.
Treatment non-completion may occur with radiotherapy (RT), especially with protracted treatment courses such as RT for prostate cancer, and may affect the efficacy of RT. For men with localized prostate cancer managed with primary RT, we evaluated associations between rates of treatment non-completion and RT fractionation schedules.
External beam radiotherapy (EBRT) with brachytherapy boost reduces cancer recurrence in patients diagnosed with prostate cancer compared to EBRT monotherapy. However, randomised controlled trials or large-scale observational studies have not compared brachytherapy boost types directly.
